ADMA Biologics, Inc. · 4 hours ago
Engineer, Validation
ADMA Biologics is a biopharmaceutical company committed to creating superior products for immunodeficient patients at risk for infection. The Engineer, Validation provides validation support to Immunotherapy Production, Quality Control, and Plant Engineering, ensuring compliance with all quality policies and standards.
BiotechnologyHealth CareManufacturingMedical
Responsibilities
Provides validation support to Immunotherapy Production, Quality Control and Plant Engineering
Provides activity updates to Validation Manager on a regular basis to ensure compliance issues are being met
Ensures compliance with all ADMA Quality policies, standards, and SOPs in their area of work and responsibility
Ensures all Quality Assurance (QA) records and reports, Human Resources (HR) policies, and Environmental Health and Safety (EH&S) procedures and practices are completed in a timely manner
Communicates/escalates any delay or failure to comply with policies, standards and procedures to the appropriate responsible parties, such as QA, HR, or EH&S depending on the issue
Qualification
Required
Bachelor's degree in science or engineering
3+ years validation experience in a cGMP, Pharmaceutical/Biological manufacturing environment
Benefits
401K plan with employer match and immediate vesting
Medical, Vision, Life and Dental Insurance
Pet Insurance
Company paid STD and LTD
Company Paid Holidays
3 Weeks’ Paid Time Off (within the first year)
Tuition Assistance (after the first year)
Easily accessible to Tri-Rail. Free shuttle to the Boca Tri-Rail station
Company
ADMA Biologics, Inc.
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
Funding
Current Stage
Public CompanyTotal Funding
$1.04BKey Investors
JP MorganAres ManagementHayfin Capital Management
2025-08-06Post Ipo Debt· $300M
2023-12-18Post Ipo Debt· $135M
2022-12-07Post Ipo Equity· $60M
Recent News
MarketScreener
2026-01-05
2025-11-07
Company data provided by crunchbase